Search results
Therapy developer Alumis seeks up to $1 bln valuation in US IPO
Reuters· 2 days agoAlumis is targeting a valuation of up to $1.01 billion in its initial public offering in the United...
6 Ways To Build Wealth After Getting Laid Off — That Don’t Include a New Job
GOBankingRates via Yahoo Finance UK· 3 days agoLayoffs are a fact of life in the modern economy -- even when the economy is growing and...
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
Benzinga via Yahoo Finance UK· 3 days agoOn Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo...
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Zacks via Yahoo Finance UK· 3 days agoBristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it...
A FTSE 250 growth share I’d buy to target a multibagger return
Fool.co.uk via Yahoo Finance UK· 4 days agoI've been looking for a FTSE 250 growth stock to add to my 2024 Stocks and Shares ISA. I think I...
Biden administration touts lower costs for 64 prescription drugs
The Hill via Yahoo News UK· 4 days agoThe Biden administration on Wednesday announced some Medicare beneficiaries will save money on 64...
Will Bristol Myers Squibb Stock Rebound To Its 2022 Highs Of $80?
Forbes· 4 days agoBristol Myers Squibb stock (NYSE: BMY) currently trades at $42 per share, 47% below its...
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
Zacks via Yahoo Finance UK· 5 days agoBristol Myers Squibb (BMY) ended the recent trading session at $42.19, demonstrating a -0.09% swing...
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
Zacks via Yahoo Finance UK· 6 days agoBristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted...
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain...
Benzinga via Yahoo Finance UK· 6 days agoFriday, the FDA granted accelerated approval to Bristol Myers Squibb & Co’s (NYSE:BMY) Krazati...